H2020Индивидуална стипендия2019–2021

CHyMERA · Monitoring cancer heterogeneity based on the dynamic assessment of the Warburg effect under metabolic perturbation

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-05-02 → 2021-05-01
Финансиране от ЕС: 159 815 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Методът CHyMERA следи движението на глюкозата и лактата в тумори при мишки, за да оцени разпространението на рак на гърдата и мозъка. Това помага за по-доброто разбиране на разнородността на туморите и техния потенциал за метастазиране.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Monitoring cancer heterogeneity based on the dynamic assessment of the Warburg effect under metabolic perturbation

CHyMERA aimed to provide a noninvasive molecular magnetic resonance imaging methodology able to contrast and quantify tumor heterogeneity with regards to proliferation status and metastatic potential. This entails dramatic implications for clinical management, particularly in the context of brain tumors (glioblastoma) and breast cancer, respectively. Thus, the initial aims of the project were to develop the CHyMERA methodology, based on dynamic monitoring of glucose and lactate kinetics in tumors, and use it to assess tumor proliferation in mouse models of glioblastoma. Additionally, we proposed a pilot study to investigate CHyMERA’s ability for assessing metastatic potential in breast cancer models.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cancer heterogeneity is reflected in the multitude of phenotypes found in the clinic, with different proliferation statuses and metastatic potentials. These features cannot be assessed with the molecular imaging methods commonly available for diagnosis and monitoring. The main goal of this proposal is to develop a molecular imaging methodology based on endogenous contrast – CHyMERA – and demonstrate its feasibility to image hotspot areas of active proliferation and metastatic potential. The approach is based on the concept of cancer metabolic plasticity, does not require contrast agents or radioactive tracers, and should ultimately provide more specificity to cancer diagnosis and treatment planning than other imaging methods currently available. We propose to use animal models of human cancer, a glucose-enhanced imaging method, and an objective analysis of regional metabolic responses to controlled, reversible changes in the tumour microenvironment (perturbations), such as transient hypoxia. Specifically, we will (i) develop and validate CHyMERA at ultra-high magnetic fields, to monitor the metabolic kinetics of glucose and lactate in the tumour microenvironment. This methodology will be (ii) applied in vivo to two immunocompetent mouse model of GBM (allograft and genetically engineered models), to image vascular permeability/perfusion and hotspots of glioma proliferation. Finally, we will (iii) carry out a pilot study with two isogenic mouse models breast of cancer, metastatic and non-metastatic, to generate hotspots maps of proliferation and metastatic potential. All in vivo results will be validated post-mortem by immunohistochemistry. If successful, this methodology has a strong potential for clinical translational, which the host institution is ideally suited to test.

Оригинален текст от CORDIS (на английски).

Участници

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · LISBOAКоординаторПортугалия